Comprehensive medication guide to Atogepant including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0/month for eligible commercially insured patients using the AbbVie Qulipta Complete Savings Card; $250–$300/month on Medicare Part D (Tier 5, ~25% coinsurance); prior authorization required by most commercial and Part D plans.
Estimated Cash Pricing
$1,185–$1,600 per month (30-day supply) for brand-name Qulipta; no generic available as of 2026. GoodRx Gold can reduce cost to approximately $1,052–$1,109; SingleCare offers coupons to approximately $1,018.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Atogepant is the generic name for Qulipta, a prescription oral tablet manufactured by AbbVie Inc. It belongs to a class of drugs called CGRP receptor antagonists — also known as gepants. The FDA first approved atogepant in September 2021 for the preventive treatment of episodic migraine in adults, and expanded the indication to include chronic migraine prevention in March 2023.
Unlike older migraine preventives that were originally developed for other conditions, atogepant was specifically designed to target the CGRP pathway — the biological cascade that drives migraine attacks. It is taken once daily as a tablet in 10 mg, 30 mg, or 60 mg strengths and is not used for acute (rescue) treatment.
Atogepant is not a controlled substance. It does not carry a boxed warning. As of 2026, no FDA-approved generic version is available — only AbbVie's brand-name Qulipta is on the market.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Atogepant works by blocking CGRP (calcitonin gene-related peptide) receptors in the brain and nervous system. CGRP is a neuropeptide found in high concentrations in the trigeminal nerve — the main nerve involved in headache pain. During a migraine attack, CGRP levels spike, causing vasodilation (blood vessel widening), neurogenic inflammation, and pain signal transmission.
Atogepant is a small-molecule competitive antagonist that binds to the CGRP receptor and prevents CGRP from attaching, interrupting the migraine cascade before it begins. It has an elimination half-life of approximately 11 hours, making once-daily dosing sufficient to maintain continuous receptor blockade throughout the day.
Because atogepant is a small molecule (not a large protein like the injectable CGRP antibodies), it can be taken orally and is absorbed through the gastrointestinal tract. It is primarily metabolized by the liver enzyme CYP3A4, which is why dose adjustments are needed with certain CYP3A4-affecting medications.
10 mg — tablet
Once daily oral tablet; used for episodic migraine, or as reduced dose with CYP3A4 inhibitors or in severe renal impairment
30 mg — tablet
Once daily oral tablet; intermediate dose for episodic migraine
60 mg — tablet
Once daily oral tablet; standard dose for chronic migraine; may be used for severe episodic migraine
Atogepant scores 55 out of 100 on medfinder's findability scale, indicating moderate difficulty to locate. While atogepant is not on the FDA Drug Shortage Database as of early 2026, many patients report difficulty filling prescriptions at their local pharmacy. The issues are pharmacy-level stocking gaps and insurance prior authorization barriers — not a manufacturing problem.
Most retail pharmacies don't routinely stock atogepant because it costs over $1,200 per bottle and has a smaller patient base than common generic medications. Insurance prior authorization typically takes 5–14 business days, and many plans require step therapy through generic preventives first. No generic atogepant is currently available (patent challenges became eligible in September 2025, but no ANDA has been approved).
Specialty pharmacies (CVS Specialty, Accredo, Walgreens Specialty) are the most reliable source for atogepant. medfinder can help you quickly identify which pharmacies near you have atogepant in stock, saving hours of hold time and frustration.
Atogepant is not a controlled substance and has no DEA scheduling requirements, which means any licensed prescriber with prescribing authority can write a prescription. There are no federal restrictions limiting prescribing to specialists. However, some insurance prior authorization requirements may prefer documentation from a neurologist or headache specialist.
Telehealth providers can also prescribe atogepant, making it accessible for patients in rural areas or those facing long neurology wait times. Many telehealth platforms can connect patients with a prescriber within 24–72 hours — significantly faster than the typical 3–6 month wait for an in-person neurology appointment in many markets.
No. Atogepant (Qulipta) is not a controlled substance and has no DEA scheduling. It does not carry a risk of abuse or dependence, and no special prescribing restrictions apply. Any licensed prescriber with prescribing authority can write a prescription for atogepant, including primary care physicians, nurse practitioners, physician assistants, and telehealth providers.
Patients can receive refills on a standard prescription. There are no quantity limits imposed by DEA scheduling, though individual insurance plans may impose their own quantity or refill restrictions as part of prior authorization and coverage terms.
The most common side effects reported in clinical trials (occurring in at least 4% of patients) are:
Know what you need? Skip the search.
Nurtec ODT (Rimegepant)
Oral CGRP receptor antagonist (gepant); 75 mg every other day for prevention; also approved for acute migraine treatment — dual-indication convenience
Aimovig (Erenumab)
Monthly subcutaneous injection (70 mg or 140 mg); CGRP receptor antibody; first FDA-approved CGRP treatment (2018); no daily pill required
Ajovy (Fremanezumab)
Subcutaneous injection monthly (225 mg) or quarterly (675 mg); targets CGRP molecule directly; dosing flexibility with quarterly option
Emgality (Galcanezumab)
Monthly subcutaneous injection (120 mg, 240 mg loading dose); also FDA-approved for episodic cluster headache
Topiramate (Topamax)
Generic anticonvulsant; often required as step therapy before CGRP drugs; under $30/month; different side effect profile (cognitive effects, weight loss)
Prefer Atogepant? We can find it.
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin)
majorIncrease atogepant exposure; reduce dose to 10 mg/day for episodic migraine; avoid for chronic migraine
Strong/moderate CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort)
majorDecrease atogepant exposure; increase dose to 30–60 mg/day to maintain efficacy
OATP inhibitors (cyclosporine, fostemsavir)
majorIncrease atogepant exposure via transporter inhibition; reduce dose to 10–30 mg/day
HIV antivirals — protease inhibitors (ritonavir, atazanavir)
majorStrong CYP3A4 inhibitors; dose reduction to 10 mg/day required for episodic migraine
Grapefruit juice
moderateInhibits intestinal CYP3A4; may increase atogepant levels; avoid or limit consumption
Antifungals (voriconazole, posaconazole)
majorStrong CYP3A4 inhibitors; dose reduction required when co-administered
Atogepant represents a meaningful advance in migraine prevention. As the first oral CGRP receptor antagonist specifically developed as a preventive (rather than repurposed from another condition), it offers a targeted approach with a favorable tolerability profile compared to older preventives. The once-daily tablet is convenient, it's not a controlled substance, and for patients with commercial insurance who can access the AbbVie savings card, the out-of-pocket cost can be reduced to as little as $0/month.
The primary challenges in 2026 remain access and cost: many retail pharmacies don't stock it, most insurance plans require prior authorization, and there is no generic alternative yet. These are solvable problems with the right strategies — specialty pharmacy routing, proactive PA submissions, and manufacturer savings programs.
If you're having trouble finding atogepant at a pharmacy near you, medfinder can help. medfinder contacts pharmacies on your behalf, identifies which ones have your medication in stock, and texts you the results — so you can spend your time managing your health, not navigating pharmacy hold queues.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini